---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-22-000130"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:39:46.590922+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q1 2022 revenue up 15% to $7.81B; reported EPS $2.10, non-GAAP $2.62; raises guidance

## Summary
- Revenue $7.81B (+15% YoY); volume growth 20%; core product sales up 13 ppt.
- Reported EPS $2.10 (+41%); non-GAAP EPS $2.62 (+63%); both include $0.15 charges.
- 2022 EPS guidance raised: reported $7.30-$7.45; non-GAAP $8.15-$8.30.
- Tirzepatide SURMOUNT-1 obesity Phase 3: up to 22.5% weight loss; 63% of high-dose group lost ≥20% body weight.
- FDA accepted mirikizumab submission for UC; Jardiance EMPA-KIDNEY trial stopped early for positive efficacy.

## SEC filing metadata
- accession: 0000059478-22-000130
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/0000059478-22-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/lly-20220428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-22-000130
- JSON: https://secwatch.observer/filing/0000059478-22-000130.json
- Plain text: https://secwatch.observer/filing/0000059478-22-000130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.